๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Investigating centre effects in a multi-centre clinical trial of superficial bladder cancer

โœ Scribed by Takuhiro Yamaguchi; Yasuo Ohashi


Publisher
John Wiley and Sons
Year
1999
Tongue
English
Weight
112 KB
Volume
18
Category
Article
ISSN
0277-6715

No coin nor oath required. For personal study only.

โœฆ Synopsis


This paper examines the amount of variation among centres and estimates the overall e!ect of therapy in a multi-centre cancer clinical trial with censored failure time data. To investigate the centre e!ects, the variation in the treatment e!ect must be taken into consideration in addition to the variation in the baseline risk. We treat centre e!ects as random ones and extend the penalized partial likelihood approach proposed by McGilchrist to estimate the treatment-by-centre interaction as well as the baseline risk. This method is applied to data from a super"cial bladder cancer clinical trial investigating the e$cacy of intravesical chemotherapy after transurethral resection. In this trial, although there exists some degree of centre variation, especially in the baseline risk, the treatment is e!ective in preventing recurrence among the participating centres. This result indicates that the treatment e!ect is generalizable to the target population.


๐Ÿ“œ SIMILAR VOLUMES


A Bayesian hierarchical survival model f
โœ Yutaka Matsuyama; Junichi Sakamoto; Yasuo Ohashi ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 159 KB ๐Ÿ‘ 2 views

In randomized clinical trials comparing treatment effects on diseases such as cancer, a multi-centre trial is usually conducted to accrue the required number of patients in a reasonable period of time. While we interpret the average treatment effect, it is necessary to examine the homogeneity of the

A comparison of various estimators of a
โœ B. Jones; D. Teather; J. Wang; J. A. Lewis ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 96 KB ๐Ÿ‘ 1 views

When a clinical trial is conducted at more than one centre it is likely that the true treatment effect will not be identical at each centre. In other words there will be some degree of treatment-by-centre interaction. A number of alternative approaches for dealing with this have been suggested in th

Testing for centre effects in multi-cent
โœ Per Kragh Andersen; John P. Klein; Mei-Jie Zhang ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 115 KB ๐Ÿ‘ 2 views

The problem of testing for a centre e!ect in multi-centre studies following a proportional hazards regression analysis is considered. Two approaches to the problem can be used. One "ts a proportional hazards model with a "xed covariate included for each centre (except one). The need for a centre spe

A multi-centre randomized trial of two d
โœ Natalia Visalli; Maria G. Cavallo; Alberto Signore; Marco G. Baroni; Raffaella B ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 70 KB

Background Intensive insulin therapy is the gold standard by which Type 1 diabetes is treated. In addition to this therapy, administration of nicotinamide (NA) can be beneยฎcial. This concept is reinforced by the results of a recent meta-analysis of the use of NA in patients with recent-onset Type 1

Randomized trial of treatment with cispl
โœ Thierry Dorval; Sylvie Nรฉgrier; Christine Chevreau; Marie-Franรงoise Avril; Danie ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 88 KB ๐Ÿ‘ 1 views

## Background: The objective of the current study was to evaluate the response rate, survival, and toxicity of treatment with cisplatin and high dose intravenous continuous infusion interleukin-2 (il-2) with or without interferon-alpha-2a (ifn) in patients with metastatic melanoma. ## Methods: On